# US 7,608,264 B2 · Antibodies that bind to pleiotrophin growth factor receptor > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,608,264 B2 - Document ID: US7608264B2 - Status: Granted - Kind: B2 - Application number: 11/436,244 - Filed: 2006-05-18 - Published: 2009-09-17 - Granted: 2009-10-27 - Earliest claimed: 2000-06-14 - Assignees: Georgetown University - Inventors: Anton Wellstein - Web page: https://patentgrep.com/patent/US7608264B2 ## CPC - C07K 14/71: for growth factors; for growth regulators - A61P 35/00: Antineoplastic agents - C07K 14/475: Growth factors; Growth regulators - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders. ## Claims ### Claim 1 An isolated monoclonal antibody or antibody fragment which binds a pleiotrophin-binding fragment of human Anaplastic Lymphoma Kinase (ALK) and inhibits a pleiotrophin-mediated activity. ### Claim 2 (depends on 1) The isolated antibody or antibody fragment of claim 1, wherein the pleiotrophin-binding fragment of ALK comprising a MAM domain. ### Claim 3 (depends on 1) The antibody or antibody fragment of claim 1, wherein the antibody is specifically reactive against the amino acid sequence of positions 368-447 of the polypeptide sequence of SEQ ID NO: 2. ### Claim 4 (depends on 1) The antibody or antibody fragment of claim 1, wherein the antibody is specifically reactive against the amino acid sequence of positions 391-401 of the polypeptide sequence of SEQ ID NO: 2. ### Claim 5 (depends on 1) The isolated antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment inhibits pleiotrophin binding to ALK. ### Claim 6 (depends on 1) The isolated antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment inhibits a pleiotrophin-mediated neoplastic or mitogenic activity. ### Claim 7 (depends on 1) The isolated antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment inhibits angiogenesis. ### Claim 8 (depends on 1) The isolated antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment blocks activation of ALK. ### Claim 9 (depends on 1) The isolated antibody or antibody fragment of claim 1, wherein the antibody or antibody fragment is selected from the group consisting of a monoclonal antibody, an IgG, an IgM, a human antibody, a humanized antibody, a Fab fragment, and an Fv fragment. ### Claim 10 A hybridoma which produces a monoclonal antibody that binds a pleiotrophin-binding fragment of human ALK and inhibits a pleiotrophin-mediated activity. ### Claim 11 (depends on 1) A pharmaceutical composition comprising the isolated antibody or antibody fragment of claim 1.